Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kanaga Sabapathy

Showing results (1-10 of 89) with videos related to

Pageof 9
Sort By:
Frontiers in Oncology|December 24, 2015
The Contrived Mutant p53 Oncogene - Beyond Loss of FunctionsKanaga Sabapathy
Molecular and Cellular Biology|December 30, 2015
p73: a Positive or Negative Regulator of Angiogenesis, or Both?Kanaga Sabapathy
Progress in Molecular Biology and Translational Science|February 21, 2012
Role of the JNK pathway in human diseasesKanaga Sabapathy
Frontiers in Oncology|April 19, 2021
Corrigendum: The Contrived Mutant p53 Oncogene - Beyond Loss of FunctionsKanaga Sabapathy
Proteomics|October 1, 2019
RNF4-A Paradigm for SUMOylation-Mediated UbiquitinationRamesh Kumar, Kanaga Sabapathy
International Journal of Cancer|June 2, 2011
JNK1 and JNK2 play redundant functions in Myc-induced B cell lymphoma formationMoorthy Anbalagan, Kanaga Sabapathy
Cellular Signalling|October 13, 2009
Tyrosine 170 is dispensable for c-Jun turnoverMin Xie, Kanaga Sabapathy
The Journal of Biological Chemistry|May 28, 2005
Transactivation-dependent and -independent regulation of p73 stabilityIqbal Dulloo, Kanaga Sabapathy
Cell Death and Differentiation|June 25, 2025
p53 prophylactic therapy for cancer preventionChristian Krueger, Kanaga Sabapathy
Cell Cycle (Georgetown, Tex.)|December 22, 2004
JNK2: a negative regulator of cellular proliferationKanaga Sabapathy, Erwin F Wagner
Pageof 9

Showing results (1-10 of 89) with videos related to

Sort By:
Pageof 9
Frontiers in Oncology|December 24, 2015
The Contrived Mutant p53 Oncogene - Beyond Loss of FunctionsKanaga Sabapathy
Molecular and Cellular Biology|December 30, 2015
p73: a Positive or Negative Regulator of Angiogenesis, or Both?Kanaga Sabapathy
Progress in Molecular Biology and Translational Science|February 21, 2012
Role of the JNK pathway in human diseasesKanaga Sabapathy
Frontiers in Oncology|April 19, 2021
Corrigendum: The Contrived Mutant p53 Oncogene - Beyond Loss of FunctionsKanaga Sabapathy
Proteomics|October 1, 2019
RNF4-A Paradigm for SUMOylation-Mediated UbiquitinationRamesh Kumar, Kanaga Sabapathy
International Journal of Cancer|June 2, 2011
JNK1 and JNK2 play redundant functions in Myc-induced B cell lymphoma formationMoorthy Anbalagan, Kanaga Sabapathy
Cellular Signalling|October 13, 2009
Tyrosine 170 is dispensable for c-Jun turnoverMin Xie, Kanaga Sabapathy
The Journal of Biological Chemistry|May 28, 2005
Transactivation-dependent and -independent regulation of p73 stabilityIqbal Dulloo, Kanaga Sabapathy
Cell Death and Differentiation|June 25, 2025
p53 prophylactic therapy for cancer preventionChristian Krueger, Kanaga Sabapathy
Cell Cycle (Georgetown, Tex.)|December 22, 2004
JNK2: a negative regulator of cellular proliferationKanaga Sabapathy, Erwin F Wagner
Pageof 9